L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

NCT04924413 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER_GOV

Sponsor class

Stopped Slow enrollment

Conditions

Malignant Melanoma

Interventions

DRUG: Tislelizumab

Sponsor

Quanli Gao